Related Experiment Video
Updated: Aug 29, 2025

Author Spotlight: Advancements in iPSCs and Genetic Disease Research
Published on: October 20, 2023
Safety and biodistribution of exosomes derived from human induced pluripotent stem cells
Zhewei Gu1, Zhiyu Yin1, Pengbo Song1
1Medical College, Guangxi University, Nanning, China.
Abstract:
As a new cell-free therapy, exosomes have provided new ideas for the treatment of various diseases. Human induced pluripotent stem cells (hiPSCs) cannot be used in clinical trials because of tumorigenicity, but the exosomes derived from hiPSCs may combine the advantages of iPSC pluripotency and the nanoscale size of exosomes while avoiding tumorigenicity. Currently, the safety and biodistribution of hiPSC-exosomes in vivo are unclear. Here, we investigated the effects of hiPSC-exosomes on hemolysis, DNA damage, and cytotoxicity through cell experiments. We also explored the safety of vein injection of hiPSC-exosomes in rabbits and rats. Differences in organ distribution after nasal administration were compared in normal and Parkinson's disease model mice. This study may provide support for clinical therapy and research of intravenous and nasal administration of hiPSC-exosomes.
More Related Videos
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
Stem Cell Culture
Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
iPS Cell Differentiation

